Diego Rodriguez

#Radonc
Radiation Oncologist Hospital Mater Dei Salvador

[PDBrown @PDBrownOnc]

ASCO2026: Asymptomatic brain met EGFR/ALK NSCLC any benefit upfront cranial RT on this Randomized trial?
- Upfront RT ↑↑ brain control, no benefit PFS, OS
- Selection criteria high risk (e.g. larger size) for upfront RT is key
https://t.co/1CM31nbxeL

[NEJM @NEJM]

Presented at #ASCO26:

Among patients with previously treated metastatic pancreatic ductal adenocarcinoma, the RAS(ON) inhibitor daraxonrasib led to significantly longer overall survival and progression-free survival than chemotherapy. Full phase 3 RASolute 302 trial results: https://t.co/xwLWBZYRzq

@ASCO

[Dr Amol Akhade @SuyogCancer]

Another money 💰 slide.
Summary of all adjuvant targeted therapy trials in Resectable NSCLC. Taken from the talk by @ROsarogiagbon @ASCO #asco26

[Toni Choueiri, MD @DrChoueiri]

@chrissweens1 presents level 1B evidence from ENZAMET suggesting Decipher GC >0.85 may identify pts deriving benefit from docetaxel intensification alongside ADT + enzalutamide, while no clear benefit signal was observed for GC ≤0.85.
#ASCO26 #ProstateCancer
@O@OncoAlert @ASCO @OncBrothers

[Daniel E Spratt @DrSpratticus]

2/n #ASCO26
The design.
Peri-operative ADT (12m) + RP vs
Peri-operative ADT+Apa (12m) + RP

Robustly blinded, placebo controlled.

Some may criticize that the SOC is not RP+ADT, but simply RP, but others may state this raises the bar to show benefit of apalutamide.

@WallisCJD @HimanshuNagarMD @ChapinMD @CaPsurvivorship @wandering_gu

[PDBrown @PDBrownOnc]

🚨🚨 ASCO 2026 Final Results Randomized trial resected brain met Brachytherapy vs Post-Op SRS🚨
- Incredible Surg Bed Control with Brachy (↑↑OS as well)
- Surg bed recurrence 12% SRS vs 1% GammaTile

[Luis Moreno Sánchez @radioncoluis]

Definitive Radiotherapy to the Primary Tumor in Stage IV NSCLC: A Consensus Statement From the International Association for the Study of Lung Cancer Advanced Radiation Technology
Subcommittee

https://t.co/iPbTjLcCLi

[John Christodouleas @Xristodouleas]

Team @Sunnybrook just published in the @IJROBP a wonderful secondary dosimetric analysis of the UNITED Trial on MRgRT for #GBM. I think Figure 5 from the manuscript makes a compelling case for change. It suggests that static radiotherapy, even with large conventional margins, under‑covers the small adaptive PTV.

https://t.co/5P29k51hPt

@mr_linac, @jaydetsky @SahgalArjun

[UroToday.com @urotoday]

ARTO Trial: Long-term overall survival analysis from a randomized phase II trial testing the benefit of SBRT addition to abiraterone acetate in oligometastatic #CRPC patients. Presentation by @GiulioFrancoli1 @AOUCareggi. #GU26 written coverage by @RKSayyid @UAUrology > https://t.co/kWzd2v266x @ASCO

[Krishan Jethwa @KrishanJethwa]

🚨CONVERT🚨

LARC with clear MRF
N=663
🔎nCAPOX x 4 vs. nCRT

LRRFS: 96.3% vs 97.4% (non-inf not established)
DFS3: 89.2% vs 87.9% (p=NS)
OS3: 95% vs 94% (p=NS)

🔑Another important study for LARC! This should be viewed in the greater context of:
❓How can we best balance cancer control and long term quality of life/function for our patients
- sometimes that is RT omission
- sometimes that is organ preservation
- sometimes TNT remains ideal

https://t.co/3sDwATrNQE

@ASCO @JCO_ASCO

[Adela @adelapoite]

Metastasis-Directed Therapy in Oligometastatic Prostate Cancer - The ASCO Post https://t.co/gMAxITwN97

[Joe Y Chang @JoeChangMD]

5-20 brain mets, SRS improved quality of life as compared with HA-WBRT.

[MV Chandrakanth @ChandrakanthMv]

Can we safely omit radiation in rectal cancer?
PROSPECT, FOWARC & CONVERT give a nuanced answer 👇
🟢 Mid-rectum, MRF-negative → chemo-alone reasonable
🟡 <5 cm → individualize
🔴 Threatened MRF/T4b → RT/TNT
De-escalate wisely. #RectalCancer #Oncology #MVOnco

[ASTRO @ASTRO_org]

New in the #RedJournal: replanned TROG 12.01 unilateral cases to define guidelines for unilateral RT planning with maximal midline and contralateral sparing. @TROGfightcancer #RadOnc #HNcsm https://t.co/yvE7RTRk3A

[Felipe Couñago PhD @fcounago]

📃PSMA PET after RT ≠ straightforward.
Inflammation, fibrosis & PSMA flare can mimic progression, and quantitative PET biomarkers still lack validation.

👏 Congrats to all authors, especially Victoria Vera (part of her PhD thesis)

🔗 Free access: https://t.co/u7gxFLKoxf

[Dr Rishabh Jain @DrRishabhOnco]

🔍 PSA can stay quiet while cancer progresses.
New ENZAMET post-hoc analysis shows radiographic progression without PSA rise in mHSPC is real, common, and dangerous.

🧪 Study essentials
•Retrospective analysis of ENZAMET (ANZUP 1304)
•n = 1125 mHSPC patients
•Enzalutamide vs standard NSAA ± docetaxel

📊 Key findings
•Discordant progression (DP) in 10% overall
•Accounts for ~30% of all progression events
•5-yr OS: 24% (DP) vs 42% (other progression)
•Enzalutamide delayed DP (HR 0.66) and OP (HR 0.37)

🧠 Clinical takeaway
•PSA alone is not enough
•DP carries worse survival irrespective of treatment
•Supports regular scheduled imaging, not only PSA-triggered scans

⚠️ Why it matters
•Silent radiographic progression risks late treatment switch
•Highlights biological heterogeneity in mHSPC

📌 Bottom line
In mHSPC, no PSA rise ≠ no progression.
Imaging needs to stay proactive.

🔖 Save for clinic
📖 Full paper in comment ⬇️

#OncoTwitter #MedTwitter #ProstateCancer #mHSPC
@OncoAlert @myesmo @esmo_open @asco

[Adam B. Weiner, MD @Adam_Weiner535]

🚀 MDT in oligometastatic #ProstateCancer 🚀

👉WOLVERINE IPD meta-analysis in @TheLancetOncol

🧪 7 randomized trials, 574 pts
📉 MDT → ↓ progression, ↓ radiographic progression, ↓ time to CRPC
🔁 Consistent benefit across SOC (obs, ADT, ARPI)
🛡️ Low toxicity, short treatment courses
⚖️ OS not definitive; but this is the strongest evidence yet to integrate MDT

👏 @ChadTangMD @piet_ost

🔗 to study https://t.co/OtIHw4RGgV
🔗 to editorial https://t.co/aeWi3Wx0ms

@PCFnews @urotoday @UrologyTimes

[Daniel Chang @Dan_ChangMD]

Hot off the presses, ReCOG consensus statement endorsed by multiple Rad Onc societies now in @TheLancetOncol. Major step forward for advancing reirradiation. Congrats to authors, in particular @DrKCParadis, @ChuckMayoPhD, @elizapowerpuff.
@UMichRadOnc.

https://t.co/tJqsL28ltz

[Dr. Nina Niu Sanford @NiuSanford]

Great presentation on advancements in RT for liver metastases.

Ablative RT can be curative, non-invasive, & efficient.

No better person than @MikeChuongMD to highlight the evolution & potential of innovative RT technologies in this space. #GI26

[Steven David @drspdavid]

Our new editorial is live! 📢
PFS & OS undervalue SABR in oligoprogression trials.
Focus on TTF, TTNT, and QoL instead—highlighting SABR as a repeatable strategic ally to systemic therapy.
👉 https://t.co/TH7FHQhYnd